Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.

about

Managing the oncologic patient with suspected pneumonia in the intensive care unit.Challenges and opportunities in the treatment of ventilator-associated pneumonia.

P2860

Q38940456-00E9EB58-88D8-4AE6-8398-635AB0C0BEF5 Q38988630-E1ADE265-DB12-47AF-A093-7A9DF789779A

P2860

Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.

Item

http://www.wikidata.org/entity/Q38783043

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Investigational drugs in phase ...... f hospital-acquired pneumonia.

@en

type

Item

label

Investigational drugs in phase ...... f hospital-acquired pneumonia.

@en

prefLabel

Investigational drugs in phase ...... f hospital-acquired pneumonia.

@en

P1476

Investigational drugs in phase ...... of hospital-acquired pneumonia

@en

P2093

Elisabeth Papiol

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

Carbapenemases: the versatile beta-lactamases

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012

Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.

Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

P304

653-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2016.1168803

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26998623

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.

about

P2860

P2860

Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921